| scholarly article | Q13442814 |
| P50 | author | Quirijn de Mast | Q89932517 |
| Cornelus C Hermsen | Q114367861 | ||
| Karina Teelen | Q115215275 | ||
| Laurent Rénia | Q29997936 | ||
| Georges Snounou | Q29997953 | ||
| Geert-Jan van Gemert | Q45380524 | ||
| Marga van de Vegte-Bolmer | Q45380602 | ||
| Matthew McCall | Q55176046 | ||
| Adrian Luty | Q55176085 | ||
| Robert Sauerwein | Q72530989 | ||
| Will Roeffen | Q72536015 | ||
| André van der Ven | Q87927512 | ||
| Meta Roestenberg | Q89748760 | ||
| P2093 | author name string | Jorien Wiersma | |
| Theo Arens | |||
| Joost Hopman | |||
| Ben van Schaijk | |||
| Lopke Spaarman | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| P1104 | number of pages | 10 | |
| P304 | page(s) | 468-477 | |
| P577 | publication date | 2009-07-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Protection against a malaria challenge by sporozoite inoculation | |
| P478 | volume | 361 |
| Q35128551 | A Meta-Analysis of Experimental Studies of Attenuated Schistosoma mansoni Vaccines in the Mouse Model. |
| Q64074188 | A Multi-Stage Malaria Vaccine Candidate Able to Induce Long-Lived Antibody Responses Against Blood Stage Parasites and Robust Transmission-Blocking Activity |
| Q50026725 | A Plasmodium parasite with complete late liver stage arrest protects against pre-erythrocytic and erythrocytic stage infection in mice |
| Q39441716 | A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens |
| Q51417360 | A Specific PfEMP1 Is Expressed in P. falciparum Sporozoites and Plays a Role in Hepatocyte Infection. |
| Q36762618 | A T-cell response to a liver-stage Plasmodium antigen is not boosted by repeated sporozoite immunizations |
| Q37314756 | A chimeric protein-based malaria vaccine candidate induces robust T cell responses against Plasmodium vivax MSP119. |
| Q44164288 | A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines |
| Q34232909 | A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate |
| Q34753532 | A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites |
| Q28730779 | A hybrid multistage protein vaccine induces protective immunity against murine malaria |
| Q35375333 | A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection |
| Q36219507 | A new malaria antigen produces partial protection against Plasmodium yoelii challenge |
| Q35618598 | A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion |
| Q28476638 | A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs |
| Q40500189 | A potent adjuvant effect of a CD1d-binding NKT cell ligand in human immune system mice |
| Q40210139 | A prime-boost immunization regimen based on a simian adenovirus 36 vectored multi-stage malaria vaccine induces protective immunity in mice. |
| Q60914449 | A probabilistic model of pre-erythrocytic malaria vaccine combination in mice |
| Q47992091 | A recombinant Bacille Calmette-Guérin construct expressing the Plasmodium falciparum circumsporozoite protein enhances dendritic cell activation and primes for circumsporozoite-specific memory cells in BALB/c mice |
| Q58707703 | A sporozoite-based vaccination platform against human malaria |
| Q47973517 | A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidate |
| Q64889732 | A tracer-based method enables tracking of Plasmodium falciparum malaria parasites during human skin infection. |
| Q39382192 | A whole-killed, blood-stage lysate vaccine protects against the malaria liver stage |
| Q35052685 | Addition of histamine to subcutaneously injected Plasmodium berghei sporozoites increases the parasite liver load and could facilitate whole-parasite vaccination |
| Q29353761 | Adherence to chemoprophylaxis and Plasmodium falciparum anti-circumsporozoite seroconversion in a prospective cohort study of Dutch short-term travelers |
| Q21032463 | Advances and challenges in malaria vaccine development |
| Q34145333 | Advances and challenges in malaria vaccine development. |
| Q36892880 | An intensive longitudinal cohort study of Malian children and adults reveals no evidence of acquired immunity to Plasmodium falciparum infection |
| Q35991786 | Anti-malarial activity of geldanamycin derivatives in mice infected with Plasmodium yoelii |
| Q34103586 | Antibodies against PfEMP1, RIFIN, MSP3 and GLURP are acquired during controlled Plasmodium falciparum malaria infections in naïve volunteers |
| Q92965786 | Antibodies against Plasmodium falciparum malaria at the molecular level |
| Q64263863 | Antibody Biomarkers Associated with Sterile Protection Induced by Controlled Human Malaria Infection under Chloroquine Prophylaxis |
| Q61447733 | Antibody Responses to Antigenic Targets of Recent Exposure Are Associated With Low-Density Parasitemia in Controlled Human Infections |
| Q34530938 | Antibody and B cell responses to Plasmodium sporozoites |
| Q36446343 | Antibody profiles to plasmodium merozoite surface protein-1 in Cambodian adults during an active surveillance cohort with nested treatment study |
| Q34026260 | Antigen export during liver infection of the malaria parasite augments protective immunity |
| Q36041729 | Antigen-specific IL-2 secretion correlates with NK cell responses after immunization of Tanzanian children with the RTS,S/AS01 malaria vaccine |
| Q26798165 | Application of radiation technology in vaccines development |
| Q35924716 | Approaching the target: the path towards an effective malaria vaccine |
| Q33927133 | Artesunate versus chloroquine infection-treatment-vaccination defines stage-specific immune responses associated with prolonged sterile protection against both pre-erythrocytic and erythrocytic Plasmodium yoelii infection |
| Q38949224 | Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection |
| Q46559450 | Back to the future for antiparasite vaccines? |
| Q64972060 | Beyond Blood Smears: Qualification of Plasmodium 18S rRNA as a Biomarker for Controlled Human Malaria Infections. |
| Q45236645 | Big Data in Vaccinology: Introduction and section summaries |
| Q33811954 | Blood Stage Malaria Disrupts Humoral Immunity to the Pre-erythrocytic Stage Circumsporozoite Protein |
| Q34663978 | Blood stage vaccines for Plasmodium falciparum: current status and the way forward |
| Q35211003 | Blood-stage immunity to Plasmodium chabaudi malaria following chemoprophylaxis and sporozoite immunization |
| Q37761208 | Blood-stage malaria vaccines - recent progress and future challenges |
| Q36004060 | Breadth of humoral response and antigenic targets of sporozoite-inhibitory antibodies associated with sterile protection induced by controlled human malaria infection |
| Q38607840 | Building an effective malaria vaccine pipeline to address global needs |
| Q91650290 | CD19+CD1dhiCD5hi B Cells Can Downregulate Malaria ITV Protection by IL-10 Secretion |
| Q37581819 | CD8 T cell independent immunity after single dose infection-treatment-vaccination (ITV) against Plasmodium yoelii |
| Q37698282 | CD8(+) T Cell Responses to Plasmodium and Intracellular Parasites |
| Q27323125 | CD8(+) T cells mediate robust stage-specific immunity to P. berghei under chemoprophylaxis and this protective environment is not downregulated by the presence of blood-stage infection |
| Q36055733 | CD8+ T effector memory cells protect against liver-stage malaria |
| Q40270575 | CD8+ T-cell mediated anti-malaria protection induced by malaria vaccines; assessment of hepatic CD8+ T cells by SCBC assay |
| Q36391845 | Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? |
| Q35923859 | Can immunological principles and cross-disciplinary science illuminate the path to vaccines for HIV and other global health challenges? |
| Q37846879 | Cell biology and immunology of malaria |
| Q39259814 | Chemical Attenuation in the Development of a Whole-Organism Malaria Vaccine |
| Q36275670 | Chemoprophylaxis with sporozoite immunization in P. knowlesi rhesus monkeys confers protection and elicits sporozoite-specific memory T cells in the liver |
| Q35336088 | Chloroquine neither eliminates liver stage parasites nor delays their development in a murine Chemoprophylaxis Vaccination model |
| Q36694820 | Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA |
| Q41932090 | Comparative efficacy of pre-erythrocytic whole organism vaccine strategies against the malaria parasite |
| Q28728616 | Comparison of clinical and parasitological data from controlled human malaria infection trials |
| Q90300290 | Complement in malaria immunity and vaccines |
| Q40385272 | Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects |
| Q28551311 | Complex Minigene Library Vaccination for Discovery of Pre-Erythrocytic Plasmodium T Cell Antigens |
| Q64065218 | Comprehensive Review of Human -Specific CD8+ T Cell Epitopes |
| Q46674475 | Computational screening and characterization of putative vaccine candidates of Plasmodium vivax |
| Q38961574 | Considerations for Comprehensive Analyses of Sporozoite-Based Controlled Human Malaria Infection Studies |
| Q38747458 | Controlled Human Malaria Infection Leads to Long-Lasting Changes in Innate and Innate-like Lymphocyte Populations. |
| Q44168331 | Controlled Human Malaria Infection: Applications, Advances and Challenges. |
| Q38001604 | Controlled human blood stage malaria infection: current status and potential applications |
| Q36523062 | Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites |
| Q57462998 | Controlled infection immunization using delayed death drug treatment elicits protective immune responses to blood-stage malaria parasites |
| Q38211625 | Correlates of protective immunity following whole sporozoite vaccination against malaria |
| Q38025870 | Cross-presentation by dendritic cells |
| Q33570804 | Cross-species malaria immunity induced by chemically attenuated parasites |
| Q38953222 | Cross-stage immunity for malaria vaccine development |
| Q90176718 | Current Challenges in the Identification of Pre-Erythrocytic Malaria Vaccine Candidate Antigens |
| Q33624814 | Cytokine profiles amongst Sudanese patients with visceral leishmaniasis and malaria co-infections |
| Q61811321 | Cytomegalovirus vectors expressing Plasmodium knowlesi antigens induce immune responses that delay parasitemia upon sporozoite challenge |
| Q34399831 | Cytotoxic markers associate with protection against malaria in human volunteers immunized with Plasmodium falciparum sporozoites |
| Q34606356 | DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity |
| Q36836498 | Defining rules of CD8(+) T cell expansion against pre-erythrocytic Plasmodium antigens in sporozoite-immunized mice |
| Q47969521 | Defying malaria: Arming T cells to halt malaria |
| Q64067675 | Dendritic Cell Responses and Function in Malaria |
| Q37993739 | Dendritic cells and the malaria pre-erythrocytic stage |
| Q38872073 | Development of whole sporozoite malaria vaccines |
| Q37154138 | Diagnosis and treatment based on quantitative PCR after controlled human malaria infection |
| Q35211679 | Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres |
| Q27972709 | Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine Development |
| Q35551353 | Disruption of plasmepsin-4 and merozoites surface protein-7 genes in Plasmodium berghei induces combined virulence-attenuated phenotype |
| Q41721291 | Distinct patterns of blood-stage parasite antigens detected by plasma IgG subclasses from individuals with different level of exposure to Plasmodium falciparum infections |
| Q35507886 | Drugs for malaria: something old, something new, something borrowed |
| Q33981456 | Effect of nutrient deficiencies on in vitro Th1 and Th2 cytokine response of peripheral blood mononuclear cells to Plasmodium falciparum infection. |
| Q37033079 | Effective Antimalarial Chemoprevention in Childhood Enhances the Quality of CD4+ T Cells and Limits Their Production of Immunoregulatory Interleukin 10. |
| Q35965247 | Effector Phenotype of Plasmodium falciparum-Specific CD4+ T Cells Is Influenced by Both Age and Transmission Intensity in Naturally Exposed Populations |
| Q28476346 | Effector memory Th1 CD4 T cells are maintained in a mouse model of chronic malaria |
| Q33744460 | Engineering of Genetically Arrested Parasites (GAPs) For a Precision Malaria Vaccine |
| Q33577093 | Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine |
| Q46218708 | Epidemiology of malaria in the Papua New Guinean highlands |
| Q37503103 | Estimating the per-exposure effect of infectious disease interventions |
| Q21032652 | European Vaccine Initiative: lessons from developing malaria vaccines |
| Q41989340 | Evaluation of a Plasmodium-specific carrier protein to enhance production of recombinant Pfs25, a leading transmission-blocking vaccine candidate |
| Q38857318 | Evaluation of different heterologous prime-boost immunization strategies against Babesia bovis using viral vectored and protein-adjuvant vaccines based on a chimeric multi-antigen |
| Q41003777 | Ex vivo lymphocyte phenotyping during Plasmodium falciparum sporozoite immunization in humans |
| Q38689861 | Examining cellular immune responses to inform development of a blood-stage malaria vaccine. |
| Q36690983 | Experience and challenges from clinical trials with malaria vaccines in Africa |
| Q36204459 | Experimental Immunization Based on Plasmodium Antigens Isolated by Antibody Affinity. |
| Q44156054 | Experimental human challenge infections can accelerate clinical malaria vaccine development |
| Q56378326 | Experimental infection of human volunteers |
| Q37463375 | Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers. |
| Q43642538 | Exploring immunological mechanisms of the whole sporozoite vaccination against P. falciparum malaria |
| Q28538917 | External quality assurance of malaria nucleic acid testing for clinical trials and eradication surveillance |
| Q90665758 | Fast and fierce versus slow and smooth: Heterogeneity in immune responses to Plasmodium in the controlled human malaria infection model |
| Q36125714 | Filarial infection suppresses malaria-specific multifunctional Th1 and Th17 responses in malaria and filarial coinfections |
| Q38962844 | First clinical trial of purified, irradiated malaria sporozoites in humans |
| Q35662378 | Flow Cytometry Based Detection and Isolation of Plasmodium falciparum Liver Stages In Vitro |
| Q37837477 | From vaccine practice to vaccine science: the contribution of human immunology to the prevention of infectious disease |
| Q62738086 | Functional antibodies against sporozoites are associated with a longer time to qPCR-detected infection among schoolchildren in Burkina Faso |
| Q40173318 | Genetically attenuated malaria parasites as vaccines |
| Q36811011 | Genetically engineered, attenuated whole-cell vaccine approaches for malaria |
| Q39381981 | Group 2 ILCs: A way of enhancing immune protection against human helminths? |
| Q26863301 | Helminth parasite proteomics: from experimental models to human infections |
| Q35560599 | Heterologous Protection against Malaria after Immunization with Plasmodium falciparum Sporozoites |
| Q33646573 | High Sporozoite Antibody Titers in Conjunction with Microscopically Detectable Blood Infection Display Signatures of Protection from Clinical Malaria |
| Q40715694 | High-Density Peptide Arrays for Malaria Vaccine Development |
| Q37686622 | Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria |
| Q51396948 | How do antigenically varying pathogens avoid cross-reactive responses to invariant antigens? |
| Q39510998 | Human CD8+ T cells mediate protective immunity induced by a human malaria vaccine in human immune system mice |
| Q63408452 | Human TLR8 Senses RNA From -Infected Red Blood Cells Which Is Uniquely Required for the IFN-γ Response in NK Cells |
| Q59806965 | Human Vγ9Vδ2 T Lymphocytes in the Immune Response to Infection |
| Q37329601 | Human-specific evolution of sialic acid targets: explaining the malignant malaria mystery? |
| Q52655657 | Humanized DRAGA mice immunized with Plasmodium falciparum sporozoites and chloroquine elicit protective pre-erythrocytic immunity. |
| Q36882512 | Humoral and cellular immunity to Plasmodium falciparum merozoite surface protein 1 and protection from infection with blood-stage parasites |
| Q47099112 | Humoral protection against mosquito bite-transmitted Plasmodium falciparum infection in humanized mice |
| Q36812832 | IFNγ Responses to Pre-erythrocytic and Blood-stage Malaria Antigens Exhibit Differential Associations With Past Exposure and Subsequent Protection |
| Q37458864 | IFNγ/IL-10 co-producing cells dominate the CD4 response to malaria in highly exposed children |
| Q33979932 | IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform |
| Q35867348 | Identification of Immunodominant Responses to the Plasmodium falciparum Antigens PfUIS3, PfLSA1 and PfLSAP2 in Multiple Strains of Mice |
| Q33905005 | Identification of pre-erythrocytic malaria antigens that target hepatocytes for killing in vivo and contribute to protection elicited by whole-parasite vaccination |
| Q37539836 | Idiopathic acute myocarditis during treatment for controlled human malaria infection: a case report |
| Q30561036 | Imaging Plasmodium immunobiology in the liver, brain, and lung |
| Q21032484 | Immune mechanisms in malaria: new insights in vaccine development |
| Q92844781 | Immunisation of cattle against Babesia bovis combining a multi-epitope modified vaccinia Ankara virus and a recombinant protein induce strong Th1 cell responses but fails to trigger neutralising antibodies required for protection |
| Q50041449 | Immunization of malaria pre-exposed volunteers with PfSPZ Vaccine elicits long-lived IgM invasion-inhibitory and complement-fixing antibodies |
| Q34440997 | Immunization of mice with live-attenuated late liver stage-arresting Plasmodium yoelii parasites generates protective antibody responses to preerythrocytic stages of malaria |
| Q47711225 | Immunization with Transgenic Rodent Malaria Parasites Expressing Pfs25 Induces Potent Transmission-Blocking Activity |
| Q34109763 | Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii |
| Q36686924 | Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys |
| Q37505400 | Immunogenicity, protective efficacy and safety of a recombinant DNA vaccine encoding truncated Plasmodium yoelii sporozoite asparagine-rich protein 1 (PySAP1). |
| Q46792678 | Immunological bases of increased susceptibility to invasive nontyphoidal Salmonella infection in children with malaria and anaemia. |
| Q47993642 | Immunology. Another shot at a malaria vaccine |
| Q26775212 | Immunoregulation in human malaria: the challenge of understanding asymptomatic infection |
| Q35439859 | Impact of malaria preexposure on antiparasite cellular and humoral immune responses after controlled human malaria infection |
| Q93266237 | Improving Vaccine-Induced Immunity: Can Baseline Predict Outcome? |
| Q58549248 | In utero priming of highly functional effector T cell responses to human malaria |
| Q27310073 | In vivo CD8+ T cell dynamics in the liver of Plasmodium yoelii immunized and infected mice |
| Q30043892 | Inactivation of a Plasmodium apicoplast protein attenuates formation of liver merozoites |
| Q52719272 | Inclusion of the murine IgGκ signal peptide increases the cellular immunogenicity of a simian adenoviral vectored Plasmodium vivax multistage vaccine. |
| Q37264722 | Inducing humoral and cellular responses to multiple sporozoite and liver-stage malaria antigens using exogenous plasmid DNA. |
| Q61803783 | Induction of Plasmodium-Specific Immune Responses Using Liposome-Based Vaccines |
| Q35005101 | Induction of antimalaria immunity by pyrimethamine prophylaxis during exposure to sporozoites is curtailed by parasite resistance |
| Q41857121 | Infection and treatment immunizations for successful parasite vaccines |
| Q50199352 | Infectious Sporozoites of Plasmodium berghei Effectively Activate Liver CD8α+ Dendritic Cells |
| Q38714971 | Infectivity of Plasmodium falciparum sporozoites determines emerging parasitemia in infected volunteers. |
| Q38279504 | Inflammatory responses to infection: the Dutch contribution |
| Q38865826 | Influence of infection on malaria-specific antibody dynamics in a cohort exposed to intense malaria transmission in northern Uganda |
| Q38260972 | Innate sensing of malaria parasites |
| Q36929459 | Insights into the preclinical treatment of blood-stage malaria by the antibiotic borrelidin |
| Q41938035 | Interferon-γ, a valuable surrogate marker of Plasmodium falciparum pre-erythrocytic stages protective immunity |
| Q37770828 | Interferon-γ--central mediator of protective immune responses against the pre-erythrocytic and blood stage of malaria |
| Q91898654 | Intermittent preventive treatment with dihydroartemisinin-piperaquine and risk of malaria following cessation in young Ugandan children: a double-blind, randomised, controlled trial |
| Q53702464 | Investigating zoonotic infection barriers to ape Plasmodium parasites using faecal DNA analysis. |
| Q41587442 | Isolation, production and characterization of fully human monoclonal antibodies directed to Plasmodium falciparum MSP10. |
| Q38284696 | Live attenuated pre-erythrocytic malaria vaccines |
| Q35199926 | Liver-Stage Specific Response among Endemic Populations: Diet and Immunity |
| Q34260189 | Long term protection after immunization with P. berghei sporozoites correlates with sustained IFNγ responses of hepatic CD8+ memory T cells |
| Q41932967 | Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study |
| Q35586865 | Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans |
| Q64114111 | Looking for Needles in the Plasmodial Haystack |
| Q38137752 | Looking under the skin: the first steps in malarial infection and immunity |
| Q34028638 | Low doses of killed parasite in CpG elicit vigorous CD4+ T cell responses against blood-stage malaria in mice. |
| Q28080325 | Malaria Parasites: The Great Escape |
| Q33821137 | Malaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease |
| Q58569727 | Malaria prevention: from immunological concepts to effective vaccines and protective antibodies |
| Q34340186 | Malaria vaccine R&D in the Decade of Vaccines: breakthroughs, challenges and opportunities |
| Q38854831 | Malaria vaccines and human immune responses |
| Q96607419 | Malaria vaccines since 2000: progress, priorities, products |
| Q38017529 | Malaria vaccines: focus on adenovirus based vectors. |
| Q33513966 | Malaria vaccines: where next? |
| Q37385314 | Measurement of the T Cell Response to Preerythrocytic Vaccination in Mice |
| Q35606514 | Mechanisms of stage-transcending protection following immunization of mice with late liver stage-arresting genetically attenuated malaria parasites |
| Q34563555 | Memory B-cell and antibody responses induced by Plasmodium falciparum sporozoite immunization |
| Q33826130 | Minimal role for the circumsporozoite protein in the induction of sterile immunity by vaccination with live rodent malaria sporozoites |
| Q37546462 | Model for in vivo assessment of humoral protection against malaria sporozoite challenge by passive transfer of monoclonal antibodies and immune serum |
| Q40042826 | Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial |
| Q34979479 | Multiplex qPCR for detection and absolute quantification of malaria |
| Q37478246 | Murine infection models for vaccine development: the malaria example |
| Q42246808 | NIAID meeting report: improving malaria vaccine strategies through the application of immunological principles |
| Q37689434 | NK Cells: Uncertain Allies against Malaria |
| Q47341472 | Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies |
| Q39662166 | Neospora caninum: in vivo and in vitro treatment with artemisone |
| Q34290768 | New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1 |
| Q41936153 | New medicines for malaria |
| Q47154921 | Novel Plasmodium antigens identified via genome-based antibody screen induce protection associated with polyfunctional T cell responses. |
| Q59800434 | Novel Strategies for Malaria Vaccine Design |
| Q21131082 | Novel approaches to identify protective malaria vaccine candidates |
| Q38607835 | Novel approaches to whole sporozoite vaccination against malaria. |
| Q56360727 | OX40 Stimulation Enhances Protective Immune Responses Induced After Vaccination With Attenuated Malaria Parasites |
| Q56342367 | Opportunities for Host-targeted Therapies for Malaria |
| Q34792326 | Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe |
| Q47972949 | Our impasse in developing a malaria vaccine |
| Q64115595 | Outcomes of controlled human malaria infection after BCG vaccination |
| Q28727971 | P. falciparum enhances HIV replication in an experimental malaria challenge system |
| Q50114695 | Paediatric schistosomiasis: What we know and what we need to know. |
| Q35023695 | Parasitostatic effect of maslinic acid. II. Survival increase and immune protection in lethal Plasmodium yoelii-infected mice |
| Q35623459 | Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors |
| Q33558847 | Phenotypic characterization of Plasmodium berghei responsive CD8+ T cells after immunization with live sporozoites under chloroquine cover |
| Q56355721 | Plasmodium 18S rRNA of intravenously administered sporozoites does not persist in peripheral blood |
| Q41593015 | Plasmodium attenuation: connecting the dots between early immune responses and malaria disease severity |
| Q38059751 | Plasmodium falciparum malaria vaccines: current status, pitfalls and future directions |
| Q89514056 | Plasmodium falciparum pre-erythrocytic stage vaccine development |
| Q36726849 | Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses |
| Q34419934 | Plasmodium immunomics. |
| Q44166267 | Plasmodium liver load following parenteral sporozoite administration in rodents |
| Q38818422 | Plasmodium meets AAV-the (un)likely marriage of parasitology and virology, and how to make the match |
| Q35843501 | Polyfunctional Specific Response to Echinococcus Granulosus Associates to the Biological Activity of the Cysts |
| Q37624370 | Polyfunctional and IFN-γ monofunctional human CD4+ T cell populations are molecularly distinct. |
| Q59807801 | Pre-clinical evaluation of a -based whole-sporozoite malaria vaccine candidate |
| Q36972498 | Pre-erythrocytic antibody profiles induced by controlled human malaria infections in healthy volunteers under chloroquine prophylaxis |
| Q35649424 | Preserved dendritic cell HLA-DR expression and reduced regulatory T cell activation in asymptomatic Plasmodium falciparum and P. vivax infection |
| Q41693606 | Profiling the Targets of Protective CD8+ T Cell Responses to Infection |
| Q36888465 | Profoundly Reduced CD1c+ Myeloid Dendritic Cell HLA-DR and CD86 Expression and Increased Tumor Necrosis Factor Production in Experimental Human Blood-Stage Malaria Infection |
| Q37361903 | Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines |
| Q30354426 | Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. |
| Q36835495 | Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity |
| Q39353199 | Protection against malaria by immunization with non-attenuated sporozoites under single-dose piperaquine-tetraphosphate chemoprophylaxis |
| Q49958400 | Protection from experimental cerebral malaria with a single intravenous or subcutaneous whole-parasite immunization |
| Q35094826 | Protection of Malian children from clinical malaria is associated with recognition of multiple antigens |
| Q36949510 | Protective efficacy and safety of liver stage attenuated malaria parasites |
| Q38159714 | Protective immunity against malaria after vaccination |
| Q40067174 | Protective immunity differs between routes of administration of attenuated malaria parasites independent of parasite liver load. |
| Q28068626 | Protective immunity to liver-stage malaria |
| Q37129923 | Purification of Plasmodium Sporozoites Enhances Parasite-Specific CD8+ T Cell Responses |
| Q90149697 | Quantification of wild-type and radiation attenuated Plasmodium falciparum sporozoite motility in human skin |
| Q36043731 | Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection |
| Q36143186 | Reduced Plasmodium Parasite Burden Associates with CD38+ CD4+ T Cells Displaying Cytolytic Potential and Impaired IFN-γ Production |
| Q41927711 | Reduced Plasmodium berghei sporozoite liver load associates with low protective efficacy after intradermal immunization |
| Q37698761 | Reducing empiricism in malaria vaccine design |
| Q33661363 | Role of Plasmodium berghei cGMP-dependent protein kinase in late liver stage development |
| Q37130133 | Roles of IFN-γ and γδ T Cells in Protective Immunity Against Blood-Stage Malaria |
| Q28545017 | Safety and comparability of controlled human Plasmodium falciparum infection by mosquito bite in malaria-naïve subjects at a new facility for sporozoite challenge |
| Q40068316 | Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. |
| Q36644534 | Safety, Immunogenicity, and Protective Efficacy of Intradermal Immunization with Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites in Volunteers Under Chloroquine Prophylaxis: A Randomized Controlled Trial |
| Q44141261 | Signatures of malaria vaccine efficacy in ageing murine immune memory |
| Q37254129 | Skin scarification with Plasmodium falciparum peptide vaccine using synthetic TLR agonists as adjuvants elicits malaria sporozoite neutralizing immunity |
| Q36602130 | Skin-draining lymph node priming is sufficient to induce sterile immunity against pre-erythrocytic malaria |
| Q34379539 | Spatial variation in genetic diversity and natural selection on the thrombospondin-related adhesive protein locus of Plasmodium vivax (PvTRAP). |
| Q33960093 | Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum |
| Q28544964 | Sporozoite immunization of human volunteers under mefloquine prophylaxis is safe, immunogenic and protective: a double-blind randomized controlled clinical trial |
| Q39267443 | Sterile protection against human malaria by chemoattenuated PfSPZ vaccine |
| Q37608653 | Strain-specific immunity induced by immunization with pre-erythrocytic stages of Plasmodium chabaudi |
| Q34430242 | Strain-specific protective effect of the immunity induced by live malarial sporozoites under chloroquine cover |
| Q33959038 | Strategies for designing and monitoring malaria vaccines targeting diverse antigens |
| Q35314263 | Studying the effect of chloroquine on sporozoite-induced protection and immune responses in Plasmodium berghei malaria |
| Q34852105 | Successful human infection with P. falciparum using three aseptic Anopheles stephensi mosquitoes: a new model for controlled human malaria infection |
| Q26825650 | Successful vaccines for naturally occurring protozoal diseases of animals should guide human vaccine research. A review of protozoal vaccines and their designs |
| Q35632820 | Superinfection in malaria: Plasmodium shows its iron will |
| Q33802385 | Synergistic effect of IL-12 and IL-18 induces TIM3 regulation of γδ T cell function and decreases the risk of clinical malaria in children living in Papua New Guinea |
| Q40749062 | Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen |
| Q21032488 | Systems immunology of human malaria |
| Q92802893 | T cell-mediated immunity to malaria |
| Q53698808 | T-cell responses against Malaria: Effect of parasite antigen diversity and relevance for vaccine development |
| Q37771945 | TLR9 and endogenous adjuvants of the whole blood-stage malaria vaccine |
| Q36114395 | Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. |
| Q42642943 | Taking a bite out of malaria: controlled human malaria infection by needle and syringe |
| Q98465723 | The Impact of Malaria Parasites on Dendritic Cell-T Cell Interaction |
| Q28084325 | The March Toward Malaria Vaccines |
| Q36247418 | The Power of Malaria Vaccine Trials Using Controlled Human Malaria Infection |
| Q37821798 | The apicoplast |
| Q34999392 | The case for a rational genome-based vaccine against malaria. |
| Q55353878 | The complement system contributes to functional antibody-mediated responses induced by immunization with Plasmodium falciparum malaria sporozoites. |
| Q39094542 | The intradermal route for inoculation of sporozoites of rodent malaria parasites for immunological studies. |
| Q38577638 | The march toward malaria vaccines |
| Q39032711 | The mysteries of immunity to malaria |
| Q38196455 | The path of malaria vaccine development: challenges and perspectives |
| Q40207794 | The rise and fall of malaria in a West African rural community, Dielmo, Senegal, from 1990 to 2012: a 22 year longitudinal study |
| Q96956090 | The use of proteomics for the identification of promising vaccine and diagnostic biomarkers in Plasmodium falciparum |
| Q33982957 | Toward a surrogate marker of malaria exposure: modeling longitudinal antibody measurements under outbreak conditions |
| Q39170404 | Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection |
| Q47172807 | Toxoplasma vaccines: appropriate end points and sample size in future human clinical trials |
| Q28743564 | Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1 |
| Q38430651 | Translational medicine policy issues in infectious disease |
| Q40979878 | Transmission blocking malaria vaccines: Assays and candidates in clinical development |
| Q40375973 | Trimethoprim-Sulfamethoxazole Prophylaxis During Live Malaria Sporozoite Immunization Induces Long-Lived, Homologous, and Heterologous Protective Immunity Against Sporozoite Challenge |
| Q56342012 | Understanding the Liver-Stage Biology of Malaria Parasites: Insights to Enable and Accelerate the Development of a Highly Efficacious Vaccine |
| Q64947790 | Vaccination With Sporozoites: Models and Correlates of Protection. |
| Q57180542 | Vaccination with chemically attenuated Plasmodium falciparum asexual blood-stage parasites induces parasite-specific cellular immune responses in malaria-naïve volunteers: a pilot study |
| Q34398787 | Vaccination with lipid core peptides fails to induce epitope-specific T cell responses but confers non-specific protective immunity in a malaria model |
| Q17485685 | Vaccines against malaria |
| Q39296506 | Vaccines to Accelerate Malaria Elimination and Eventual Eradication |
| Q55279637 | Varying Immunizations With Plasmodium Radiation-Attenuated Sporozoites Alter Tissue-Specific CD8+ T Cell Dynamics. |
| Q33976757 | What can we learn from an unnatural immune response? |
| Q44168891 | Wheat germ cell-free technology for accelerating the malaria vaccine research |
| Q55381231 | Whole blood transcriptome changes following controlled human malaria infection in malaria pre-exposed volunteers correlate with parasite prepatent period. |
| Q92642716 | Whole-blood transcriptomic signatures induced during immunization by chloroquine prophylaxis and Plasmodium falciparum sporozoites |
| Q33587443 | Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model |
| Q38598055 | Workshop report: Malaria vaccine development in Europe--preparing for the future. |
| Q48023186 | cGAS-mediated control of blood-stage malaria promotes Plasmodium-specific germinal center responses |
Search more.